Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
13.44
+0.46 (3.54%)
Jul 27, 2026, 4:00 PM EDT - Market closed
Greenwich LifeSciences Employees
As of December 31, 2024, Greenwich LifeSciences had 8 total employees, including 4 full-time and 4 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$2,783,822
Market Cap
197.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% | 4 | 4 |
| Dec 31, 2023 | 7 | 1 | 16.67% | 3 | 4 |
| Dec 31, 2022 | 6 | 0 | - | 3 | 3 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 3 | 3 |
| Dec 31, 2020 | 3 | - | - | 1 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Protalix BioTherapeutics | 226 |
| Immunic | 95 |
| Keros Therapeutics | 87 |
| Precision BioSciences | 66 |
| NovaBridge Biosciences | 30 |
| Whitehawk Therapeutics | 29 |
| Outlook Therapeutics | 17 |
GLSI News
- 5 days ago - Greenwich receives regulatory approval to expand Flamingo-01 in the U.K. - TheFly
- 5 days ago - Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom - GlobeNewsWire
- 6 days ago - Greenwich LifeSciences price target raised to $69 from $50 at H.C. Wainwright - TheFly
- 7 days ago - Greenwich LifeSciences provides clinical and financial updates on Flamingo-01 - TheFly
- 7 days ago - Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 - GlobeNewsWire
- 11 days ago - Greenwich announces European approval for FLAMINGO-01 population combination - TheFly
- 11 days ago - Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 - GlobeNewsWire
- 18 days ago - Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 - GlobeNewsWire